Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Center for International Blood and Marrow Transplant Research
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Groupe Francophone des Myelodysplasies
St. Jude Children's Research Hospital
Cogent Biosciences, Inc.
Emory University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Center for International Blood and Marrow Transplant Research
St. Jude Children's Research Hospital
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
City of Hope Medical Center
Ionis Pharmaceuticals, Inc.
University of Illinois at Chicago
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
University of Miami
Novartis
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
City of Hope Medical Center
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Blueprint Medicines Corporation
European LeukemiaNet
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University
Fred Hutchinson Cancer Center
City of Hope Medical Center
PharmaEssentia
St. Jude Children's Research Hospital